

Serial No.: 10/594.453

Attorney Docket No.: LNK-019

DRAFT After Final Response of June 16, 2009

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

1. (Canceled).
2. (Proposed Amendment) A process for the production of a composition containing at least one coagulation factor, comprising said process consisting of the following steps of:
 - i. adjusting the pH of the plasma fraction, wherein said plasma fraction contains an initial amount of fibronectin and at least one coagulation factor and is characterized by an ionic strength below 500 mM, to a value between pH 4.7 and pH 5.3 so as to form a precipitate comprising 70% to 99% of the initial amount of fibronectin and a supernatant containing said at least one coagulation factor, and
 - ii. removing the fibronectin precipitate formed to thereby yield a composition containing at least one coagulation factor; and
 - iii. treating the composition obtained in step ii to yield at least one purified coagulation factor.
3. (Canceled).
4. (Proposed Amendment) The process according to claim [4] 2, characterized in that the ionic strength of the plasma fraction is below 300 mM.
5. (Proposed Amendment) The process according to claim [4] 2, characterized in that the ionic strength of the plasma fraction is below 200 mM.
6. (Proposed Amendment) The process according to claim [4] 2, ~~characterized in that after adjusting the pH value in step (i), wherein step (ii) includes the step of stirring the plasma fraction is stirred~~ for at least 10 minutes.
7. (Proposed Amendment) The process according to claim [4] 2, characterized in that the majority of the fibronectin precipitate is separated by means of an agitator blade of a stirrer.
8. (Proposed Amendment) The process according to claim [4] 2, characterized in that before step (i), the fibronectin concentration in the plasma fraction initially contains fibronectin at a concentration of is at least 0.1 g per liter.

Serial No.: 10/594,453

Attorney Docket No.: LNK-019

DRAFT After Final Response of June 16, 2009

9. (Proposed Amendment) The process according to claim ~~14~~ 2, characterized in that the plasma fraction initially contains NaCl or KCl at a concentration of 100 – 200 mM.
10. (Proposed Amendment) The process according to claim ~~14~~ 2, characterized in that the plasma fraction initially contains glycine at a concentration below 500 mM.
11. (Proposed Amendment) The process according to claim ~~14~~ 2, characterized in that the plasma fraction initially contains glycine at a concentration below 200 mM.
12. (Proposed Amendment) The process according to claim ~~14~~ 2, characterized in that the plasma fraction initially contains glycine at a concentration of 50 to 200 mM.
13. (Proposed Amendment) The process according to claim ~~14~~ 2, characterized in that the plasma fraction initially contains glycine at a concentration of 100 to 150 mM.
14. (Proposed Amendment) The process according to claim ~~14~~ 2, characterized in that the plasma fraction is dissolved cryoprecipitate.
15. (Previously Presented) The process according to claim 14, characterized in that the dissolved cryoprecipitate is previously purified by (a) treatment with aluminum hydroxide, (b) treatment with a solvent and/or a detergent, and (c) anion exchange chromatography.
16. (Canceled).
17. (Proposed Amendment) The process according to claim ~~146~~ 2, characterized in that the at least one coagulation factor is von Willebrand factor.
18. (Proposed Amendment) A coagulation factor obtained by a process according to claim ~~146~~ 2.
19. (Canceled).
20. (Previously Presented) The process according to claim 2, wherein steps (i) and (ii) are performed at a temperature that ranges from 4 °C to 35 °C.
21. (Canceled).
22. (Previously Presented) The process according to claim 1, wherein steps (i) and (ii) are performed at a temperature that ranges from 20°C to 25 °C.
23. (Canceled).
24. (Previously Presented) The process according to claim 1, wherein the fibronectin precipitate obtained in step (i) contains at least 90% of the initial amount of fibronectin.